Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with Spinal Muscular Atrophy (SMA)
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date
Biogen paid Ionis a US $ 60 million one-time upfront payment
All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walking
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
_256_384.jpg)
The council has also reduced the GST to 5 per cent on a few more Covid-19 medicines
Subscribe To Our Newsletter & Stay Updated
